Dermatomyositis (DM)

What changes during this transition

Dermatomyositis is an idiopathic inflammatory myopathy with distinctive cutaneous manifestations — Gottron's papules over MCP/PIP joints, heliotrope rash over the eyelids, shawl sign across the upper back, V-sign across the anterior chest, mechanic's hands (hyperkeratotic fissuring on lateral fingers), and proximal symmetric muscle weakness. The serology defines the phenotype: anti-Mi-2 (classic skin + muscle, steroid-responsive), anti-MDA5 (clinically amyopathic DM + rapidly progressive interstitial lung disease — the life-threatening phenotype), anti-TIF1γ (cancer-associated DM in adults — 50%+ adenocarcinoma association within 3 years of diagnosis), anti-NXP2 (calcinosis + dysphagia, juvenile and adult), anti-SAE (cutaneous-dominant, late muscle involvement). The 2017 ACR/EULAR classification criteria stratify probability and incorporate biopsy when available; juvenile DM (JDM) is a distinct pediatric entity with higher calcinosis burden and characteristic vasculopathy. Standard-of-care is steroid-and-immunosuppressant-driven. High-dose corticosteroids (1 mg/kg prednisone or pulse methylprednisolone for severe disease) remain first-line for most subtypes, with steroid-sparing agents — methotrexate, azathioprine, mycophenolate mofetil — initiated early to allow taper. IVIG (Octagam 10%) received FDA approval for adult DM in 2021 based on the ProDERM trial — the first DM-specific FDA-approved therapy — and now sits in the first- or second-line conversation depending on phenotype and access. Rituximab (RIM trial evidence) covers refractory disease. JAK inhibitors (tofacitinib has the most published DM evidence, with emerging baricitinib data) are increasingly used for refractory skin disease and especially for anti-MDA5-positive DM with ILD. Cyclophosphamide and calcineurin inhibitors (tacrolimus, cyclosporine) cover anti-MDA5 rapidly progressive ILD as part of aggressive triple/quadruple therapy. Hydroxychloroquine addresses cutaneous disease. Plasmapheresis has a role in anti-MDA5 RPI-LD when conventional immunosuppression is failing. Cancer screening — age-appropriate plus risk-stratified imaging when anti-TIF1γ or anti-NXP2 is positive — is part of the initial workup. ILD surveillance with HRCT, PFTs, and anti-synthetase / anti-MDA5 antibody panels is ongoing. The ACR 2024 myositis treatment guideline and the AAD 2024 cutaneous DM guideline are the current reference frameworks. The Myositis Association (TMA) is the major US patient organization for education and support. Where Juno's library fits — narrowly and with deliberate non-elevation. No peptide has dermatomyositis evidence. The community-facing framings worth addressing honestly are (1) BPC-157 and TB-500 marketed as 'muscle healing' peptides — a category-confusion error when applied to autoimmune myositis, where the muscle injury is immune-mediated, not mechanical; (2) thymosin alpha-1 marketed as an immune modulator — directionally wrong for an autoimmune disease where the problem is immune over-activation, not under-activation; (3) Selank for steroid-induced mood disturbance — the only entry where the framing is plausibly orthogonal to the disease itself but still has serious safety concerns on chronic immunosuppression; (4) SS-31 for mitochondrial framing — DM has documented mitochondrial dysfunction histologically, which drives the community search, but no clinical evidence in DM. The honest editorial frame: rheumatology or neuromuscular specialist coordination, full myositis antibody panel for phenotyping, IVIG (Octagam FDA 2021) for first-line or steroid-sparing, JAK inhibitors for refractory skin or anti-MDA5 ILD, aggressive immunosuppression + plasmapheresis for anti-MDA5 RPI-LD, cancer screening per anti-TIF1γ / anti-NXP2 status, ILD surveillance, ACR 2024 + AAD 2024 guidelines, and Myositis Association resources drive outcomes.